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In the era of precision medicine, the impact of personalized dosing of busulfan is not clear. We undertook a retrospective
analysis of 78 patients with myeloid malignancies who received fludarabine and busulfan (FluBu4) with or without measuring Bu
pharmacokinetics (Bu PK) and those who received busulfan with cyclophosphamide (BuCy). Fifty-five patients received FluBu4,
of whom 21 had Bu PKmeasured, and 23 patients received BuCy. Total donor cell chimerism showed that the percentage of patients
maintaining 100% donor chimerism on day 100 was 66.7%, 38.2%, and 73.9% in the FluBu4 with PK, FluBu4 with no PK, and BuCy,
respectively (P = .001). Patients who had decreasing donor chimerism by day 100 were 23.8%, 52.9%, and 26.1% in the FluBu4 with
PK, FluBu4 with no PK, and BuCy, respectively (P = .04). Bu PK group had fewer patients with less than 95% donor chimerism
on day 30, which was not statistically significant, 5% (FluBu4 PK), 31% (FluBu4 with no PK), and 21% (BuCy) (P = .18). Survival
distributions were not statistically significant (P = .11). Thus, personalized drug dosing can impact donor chimerism in myeloid
malignancies. This will need to be examined in larger retrospective multicenter studies and prospective clinical trials.
1. Introduction
Allogeneic stem cell transplant (SCT) which depends on
chemotherapy and immunotherapy (graft versus leukemia
effect) is the only potential curative treatment for most
patients with acute myeloid leukemia (AML), myelodys-
plastic syndrome (MDS), and other myeloid malignancies.
However, despite the advances in allogeneic SCT, disease
relapse is still a major cause of death [1–4].
Chimerism analysis is an important tool to assess the ori-
gin of hematopoietic cells after SCT. Discrimination between
donor and recipient cells allows evaluation for engraftment
as well as detection of imminent graft rejection but its use
as prognostic indicator for relapse is controversial [5]. Many
methods have been used over the years to assess chimerism
including cytogenetics, fluorescein in situ hybridization,
and variable number of tandem repeats. However a major
limitation of most of these techniques is that they are time
consuming and without quantification.Most recently, the use
of short tandem repeats with the use of fluorescent labeling
of the primers and PCR resolution products allowed accurate
quantification of the degree of mixed chimerism [6].
Reduced toxicity ablative conditioning regimens are
increasingly used in SCT. Busulfan (Bu) has been used for
many years as a component of conditioning before SCT and
now is being used more and more especially with the intra-
venous formulation which leads to more predictable delivery
and probably improved clinical outcomes comparedwith oral
Bu [7–9]. However, even with intravenous administration,
the exposure may vary 3- to 4-fold. Recently, personalized
dosing of Bu using the patient-specific Bu clearance has been
used by some transplant centers. Target exposure is reflected
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in the measurement area under the plasma concentration-
time curve (AUC) or concentration at steady state [10].
However, its impact on early and late transplant outcomes is
not clear.
To explore the impact of measuring busulfan phar-
macokinetics (Bu PK) in conditioning regimens on early
donor chimerism in myeloid malignancies, we undertook a
retrospective analysis of patients with myeloid disorders who
received 4 days of fludarabine and busulfan (FluBu4) with
or without measuring Bu PK and busulfan and cyclophos-
phamide (BuCy) at our center in the last 10 years.
2. Materials and Methods
2.1. Patients. Patients who underwent their first allogeneic
SCT for AML,MDS, or myeloproliferative neoplasms involv-
ing myeloablative conditioning with FluBu4 or BuCy at
our center between 2005 and 2016 were included in this
retrospective analysis. Informed consent was obtained from
each patient per institutional guidelines. The institutional
review board also reviewed and approved this retrospective
analysis.
2.2. SCT Conditioning Regimen. All patients received 1 of 3
myeloablative conditioning regimens consisting of fludara-
bine 40mg/m2 with Bu 3.2mg/kg daily for 4 days with or
without Bu PK dose adjustment or Bu 3.2mg/kg for 4 days
with cyclophosphamide 60mg/kg for 2 days. The choice of
regimen was at the discretion of treating physician.
2.3. Graft versus Host Disease (GVHD) Prophylaxis. Post-
transplantation graft versus host disease (GVHD) prophy-
laxis consisted of methotrexate on days 1, 3, 6, and 11 and
tacrolimus. Patients receiving unrelated donor transplants
received antithymocyte globulin 4.5mg/kg pretransplanta-
tion in divided doses.
2.4. Chimerism Analysis. Bone marrow donor-recipient total
cell chimerism analysis was performed on day 30 and day 100
using a quantitative fluorescence-based short tandem repeat
polymerase chain reaction with capillary electrophoresis
for polymerase chain reaction product resolution. Data are
presented as peaks, and the AUC represents the percentage
of host-versus-donor hematopoiesis.
2.5. Supportive Care. All supportive care measures includ-
ing prophylactic antibiotics and antifungals were utilized
according to institutional protocols. Ursodeoxycholic acid
was started with the initiation of conditioning regimen.
2.6. Statistical Methods. Baseline characteristics were sum-
marized by transplant group. Continuous variables were
summarized as the mean, standard deviation, and range.
Categorical variables were summarized as frequency counts
and percentages. Patient and transplantation characteristics
were compared using Fisher’s exact and chi-squared test for
categorical variables andMann-Whitney’s test for continuous
variables. For overall tests, P < .05 was used to indicate
statistical significance. Engraftment was defined as achieving
an absolute neutrophil count of 500/𝜇l for 3 consecutive
days. Time of platelet engraftment was defined as the first of
3 consecutive days with a platelet count 20,000/𝜇l without
transfusion support. Criteria for complete remission (CR)
after transplant included absence of circulating blasts, less
than 5% marrow blasts, lack of chromosomal abnormalities,
and documented donor cell engraftment. Overall survival
was defined as the time from SCT to the time of death or last
contact. It was calculated using the Kaplan-Meier estimate.
3. Results
3.1. Patient and Transplant Characteristics. In this study, 78
patients were identified and included. Characteristics of the
patients are summarized in Table 1. There were 50 males and
28 females with a median age of 59 years. Diagnoses included
AML (𝑛 = 49), MDS (𝑛 = 19), and myeloproliferative
neoplasms (𝑛 = 10). Thirty-four patients had a matched
related donor, 32 had a matched unrelated donor, and 12 had
a mismatched unrelated donor SCT. Peripheral blood stem
cells were used in all patients. Fifty-five patients received
FluBu4, of whom 21 had Bu PK measured. BuCy was given
in 23 patients. Bu dose was adjusted to more than 10% change
based on PK in 81% of patients in the FluBu4 PK group. The
change was more than 15% and more than 20% of the dose in
71% and 62% of patients in the FluBu4 PK group, respectively,
median AUC targeted was 6000 uMolxMin, and median of
actual target given was 5354 uMolxMin.
Gender, donor type, cytogenetics risk group, disease
risk index, median blasts at time of SCT, CD34 dose, and
antithymocyte globulin use were comparable (𝑃 > .30)
between the 3 groups.ThemedianCD34 dosewas 3.9, 4.1, and
4.4 × 106/kg of recipient in the FluBu4 with PK, FluBu4 with
no PK, and BuCy, respectively.Themedian CD3 dose was 1.2,
1.2, and 1.1× 108/kg of recipient in the FluBu4with PK, FluBu4
with no PK, and BuCy, respectively. Antithymocyte globulin
was used in 57%, 62%, and 44% in the FluBu4 with PK,
FluBu4with noPK, andBuCy, respectively.Disease risk index
was high or very high in 57%, 53%, and 60% of patients in the
FluBu4 with PK, FluBu4 with no PK, and BuCy, respectively.
Median blasts at time of transplant were 4% in all 3 groups.
However, patients who received BuCy were younger with a
median age of 45 years compared to patients who received
FluBu4 with or without PK, 59 and 63 years, respectively (P <
.001). In addition, patients who received FluBu4 with no PK
had equal cases ofMDS (44%) andAML (44%) as a diagnosis
compared to FluBu4 with PK and BuCy who had more AML
in those groups, 71% and 82%, respectively (P = .006).
3.2. Engraftment and Chimerism. Median time to neutrophil
engraftment was 15, 12, and 14 days in the FluBu4 with PK,
FluBu4 with no PK, and BuCy, respectively. Median time to
platelet engraftment was 15, 13, and 14 days in the FluBu4with
PK, FluBu4 with no PK, and BuCy, respectively.
We evaluated total donor cell chimerism values on days
30 and 100 after allogeneic SCT as a boxplot (Figure 1). The
percentages of total donor chimerism which were grouped as
100%, 86%–99%, and less than 85% on day 30 and day 100 are
summarized in Tables 2 and 3. Total donor cell chimerism
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Table 1: Summary of patient characteristics by treatment group.
FluBu4 with PK FluBu4 without PK BuCy
P value𝑁 = 21 𝑁 = 34 𝑁 = 23
(% or range) (% or range) (% or range)
Gender M 14 (67%) M 24 (70%) M 12 (52%) .349
F 7 (33%) F 10 (30%) F 11 (48%)
Median age at time of SCT 59 (41–70) 63 (48–72) 45 (22–63) <.001
Disease .006
Acute myeloid leukemia 15 (71%) 15 (44%) 19 (82%)
MPN/MDS 6 (29%) 19 (56%) 4 (18%)
Median blasts in bone marrow at time of SCT 4% (1–40%) 4% (1–20%) 4% (1–90%) .910
Cytogenetic risk .521
High 14 (67%) 17 (50%) 14 (61%)
Intermediate 6 (29%) 16 (47%) 9 (39%)
Low 1 (4%) 1 (3%) 0 (0%)
Disease risk index .372
Intermediate 9 (43%) 16 (47%) 7 (30%)
High 5 (24%) 13 (38%) 9 (39%)
Very high 7 (33%) 5 (15%) 7 (30%)
Antithymocyte globulin use 12 (57%) 21 (62%) 10 (44%) .38
CD34 dose × 106 3.9 ± 1.5 4.1 ± 1.3 4.4 ± 2 .534
Donor type .401
Matched related donor 9 (43%) 13 (38%) 12 (52%)
Matched unrelated donor 7 (33%) 15 (44%) 10 (43%)
Mismatched unrelated donor 5 (24%) 6 (18%) 1 (5%)
Bu, busulfan; Cy, cyclophosphamide; F, female; Flu, fludarabine; M, male; MDS, myelodysplastic syndrome; MPN; myeloproliferative neoplasm; SCT, stem cell
transplant.
Table 2: Total donor chimerism on day 30.
Chimerism results at day 30 P value
FluBu4 with PK FluBu4 with no PK BuCy
100% donor 14 17 16
.31186%–99% 7 15 5
<85% 0 2 2
Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; PK, pharmacokinet-
ics.
Table 3: Total donor chimerism on day 100.
Chimerism results at day 100 P value
FluBu4 with PK FluBu4 with no PK BuCy
100% donor 14 13 17
.00686%–99% 3 12 0
<85% 4 9 6
Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; PK, pharmacokinet-
ics.
analysis showed that the percentage of patients maintaining
100% donor chimerism on day 100 was 66.7 %, 38.2%, and
73.9% in the FluBu4 with PK, FluBu4 with no PK, and BuCy,
respectively (P = .001). In addition, the percentage of patients
who had decreasing total donor chimerism by day 100 was
23.8 %, 52.9%, and 26.1% in the FluBu4 with PK, FluBu4
with no PK, and BuCy, respectively (P = .04) (Table 4). The
Bu PK group had fewer patients with less than 95% donor
chimerism by day 30 compared to the other 2 groups (no
PK and BuCy) although it was not statistically significant, 5%
(FluBu4 PK), 31% (FluBu4 with no PK), and 21% (BuCy) (P
= .18). Since patients who received BuCy were younger and
the groups who got FluBu4 with PK and BuCy had more
AML as above, we looked at multivariable analysis, which
suggested that patients treated with FluBu4 without PK had
higher odds of experiencing a decrease in chimerism from
day 30 to day 100 than patients treated with BuCy or FluBu4
with PK after adjusting for age at transplant and disease. In
addition, when we looked at the effect the treatment group
has on being in the 100% chimerism at day 100 group versus
being in the 86%–99% or less than 86% chimerism at day
100 group, adjusting for age and disease type as in Table 5,
we found that the group of FluBu4 with no PK had a higher
risk of not having 100% chimerism on day 100 with P = .066
(95% CI 0.06–1.09).
3.3. GVHD and Hepatic Venoocclusive Disease. None of the
patients in the 3 groups developed hepatic venoocclusive
disease. Grade II and grades III-IV acute GVHD were not
different between the 3 groups (P = .13). The incidence of
grade II acuteGVHDwas 19%, 17.6%, and 21.7% in the FluBu4
with PK, FluBu4 with no PK, and BuCy, respectively. Grades
III-IV acute GVHD were 4.7%, 29%, and 17.4% in FluBu4
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Figure 1: Boxplot for day 30 and day 100 chimerism for each of the
3 conditioning regimens. Bu, busulfan; Cy, cyclophosphamide; Flu,
fludarabine; PK, pharmacokinetics; SCT, stem cell transplant.
Table 4: Decreasing and nondecreasing total chimerism between
day 30 and day 100.
Decreasing
𝑁 (%)
Nondecreasing𝑁
(%) 𝑃 value
FluBu4 with no PK 18 (52.9) 16 (47.1)
.04FluBu4 with PK 5 (23.8) 16 (76.2)
BuCy 6 (26.1) 17 (73.9)
Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; PK, pharmacokinet-
ics.
Table 5: Effect on the treatment group on being in the 100%
chimerism on day 100 group versus being in the 86%–99% or <86%
chimerism on day 100, adjusting for age and disease type.
Variable OR 95% CI 𝑃 value
Treatment (versus BuCy)
FluBu4 with kinetics 0.73 0.17–3.11 .672
FluBu4 without Kinetics 0.25 0.06–1.09 .066
Age at transplant 1.01 0.96–1.06 .790
Disease 1.53 0.57–4.13 .403
Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; OR, odds ratio.
with PK, FluBu4 with no PK, and BuCy, respectively. Also
looking at patients who had total donor chimerismmore than
95% or less than 95% on day 100, rates of grade II and grades
III-IV acute GVHD were not different between the 2 groups
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Figure 2: Kaplan-Meier curve for overall survival for allogeneic
hematopoietic cell transplantation by conditioning regimen (𝑃 =
.11). BMT, bone marrow transplant; Bu, busulfan; Cy, cyclophos-
phamide; Flu, fludarabine.
(P = .43). The incidence of grade II acute GVHD was 20%
and 23% in the patients who had total donor chimerismmore
than 95% and less than 95% on day 100, respectively.
3.4. Relapse, Overall Survival, and Causes of Death. The
median survival time for all patients was 1.40 years. Relapse
rate was 24%, 47%, and 57% for FluBu4 with PK, FluBu4 with
no PK, and BuCy, respectively (𝑃 = .085). When comparing
the FluBu4 with no PK and BuCy groups, the odds ratio
of relapse within the first 3 months was 2.23 (P = .194) for
the no PK group. For the comparison of the FluBu4 with
PK and BuCy groups, the odds ratio of relapse within the
first 3 months was 1.12 (P = .87) for the FluBu4 with PK
group. Survival distributions of the 3 treatment groups were
not statistically significant (P = .11) (Figure 2). The cause of
death was relapse in 28.5%, 35.3%, and 60% of patients in
the FluBu4 with PK, FluBu4 with no PK, and BuCy groups,
respectively, while the cause of death was GVHD in in 4.7%,
5.9%, and 8.7% patients in the FluBu4 with PK, FluBu4
with no PK, and BuCy, respectively. Sepsis and liver failure
were cause of death in 8.7% of patients in the BuCy group.
Cytomegalovirus antigenemia was documented in 35%, 34%,
and 30% in the FluBu4 with PK, FluBu4 with no PK, and
BuCy, respectively.
4. Discussion
Myeloablative regimens, BuCy and FluBu4, remain the stan-
dard of care for patients undergoing SCT for AML or MDS
if they can tolerate it as recently shown by the Blood and
MarrowTransplant Clinical TrialsNetwork (BMTCTN0901)
[11] phase III randomized trial comparing reduced intensity
and myeloablative regimens in patients with AML or MDS.
This shows that intensity of chemotherapy does matter in
controlling aggressive myeloid disorders. However, not all
Advances in Hematology 5
myeloablative conditioning regimens are the same and they
differ in toxicity and nonrelapse mortality.
Although the intravenous form of Bu bypasses the influ-
ence of gastrointestinal enzymes that affects the oral form,
there is still a lot of inter- and intraindividual variabil-
ity in Bu PK [12]. The practice guidelines committee of
the American Society of Blood or Marrow Transplantation
(ASBMT) sought to develop an evidence-based review of
personalized dosing of Bu. However that was not feasible
because of the lack of the necessary controlled studies and
the published literature was too heterogeneous regarding
patient population, conditioning regimen, Bu dosing, and
Bu PK data [10]. Several studies provided recommendation
of a maximally tolerated daily exposure of Bu of less than
6,000mMxmin for 4 days [13], while others evaluated the
maximally tolerated systemic exposure of intravenous Bu in
combinationwith fludarabine and they showed that Bu can be
safely escalated to an AUC of 7000mMxmin ormore without
an appreciable difference in nonrelapse mortality [14, 15]
although with need of more patients and longer follow-up
in those studies. In our patients, the median AUC targeted
was 6000 uMolxMin and the median actual target given was
5354 uMolxMin. Bu dose had to be adjusted based on PK in
81% of patients in the FluBu4 PK group, which is similar to
the percentage reported by theCenter for International Blood
and Marrow Transplant Research (CIBMTR) where Bu dose
was adjusted based on PK in 75% of patients who got FluBu4
[16].
Many studies were published trying to compare BuCy
to FluBu4 [8, 16–19]. Most of these studies included het-
erogeneous group of patients with myeloid and lymphoid
malignancies [17, 19]; not all of them used Bu PK [17–19] nor
did they all look at chimerism kinetics [8, 16, 19]. Therefore,
not a lot of the studies were looking at the early effect on
chimerism especially in a homogeneous group of patients. In
this study we looked at the effect of these 3 regimens, BuCy,
FluBu4 with PK, and FluBu4 with no PK, on early donor
chimerism in a homogenous group of patients with myeloid
malignancies. We found that FluBu4 with PK and BuCy have
a similar effect on early donor chimerismwhile in the FluBu4
with no PK group more patients had decreasing donor
chimerism by day 100, which was statistically significant.
Even when adjusted for disease and age at transplant, FluBu4
without PK had a higher risk of decreasing donor chimerism
and more patients with less than 100% donor chimerism on
day 100. On day 30, patients who had PK performed had
lower rates of less than 95% donor chimerism compared to
others, although not statistically significant. In a randomized
trial done by Lee et al. [17], the BuFlu arm had a higher
degree of recipient chimerism and a lower probability of
complete chimerism at 4 weeks after SCT than the BuCy
arm. In addition, they had worse survival in the BuFlu group,
owing mainly to excessive disease relapse, which could be
related to the lack of targeted dosing by PK. In another
study by Liu et al. [18], patients were randomized to get
BuCy or BuFlu; fludarabine was given after busulfan. All
106 evaluable patients achieved complete donor chimerism,
defined in their study by more than 95% donor, by day
+30 after transplantation. They also looked at chimerism on
day +15 which was not statistically significant between the
2 groups but there was no mention of kinetic of chimerism
after day 30. However, their patient population included only
AML-CR1 with ages between 12 and 60 years, while our
patient population has a group of higher risk diseases.
The MD Anderson Cancer Center group looked retro-
spectively at the effect of chimerism around day 100 (days
+90 to +120) on the risk of relapse after SCT in patients with
AML (81%) or MDS (19%) who got FluBu4 [20]. All patients
received Bu 130mg/m2 daily for 4 days or Bu given with
PK dose adjustment, targeting a drug concentration AUC
of 6000mMxmin. Because of the high rates of full donor
myeloid chimerism by days +90 to +120 in all patients they
focused solely on the impact of T lymphocyte chimerism and
concluded that early T lymphocyte chimerism testing is a use-
ful approach for predicting AML/MDS disease recurrence in
patients in CR1/CR2 at the time of transplantation. However,
this study excluded patients who had disease progression
before day +120. In addition, they looked at chimerism at one
point of time without looking at changes in chimerism over
time and without comparison of groups with and without
PK. In our study we did not have data about lineage-specific
chimerism because it is not done routinely for all the patients
in our center; in addition that will create multiple small
groups of patients which would not have the power to
reflect and determine differences among those small groups.
Koreth et al. [21] looked at 688 patients with hematologic
malignancies who received FluBu to assess the impact of
early donor chimerism on long-term outcomes.They showed
that total donor chimerism independently predicts long-term
relapse and survival and also concluded that total donor cell
chimerism is sufficient and assessing T-subset chimerism is
of no additional value to predicting these endpoints. Other
studies that have suggested that such analyses cannot be
used reliably [22–25] had either different diseases, smaller
numbers of patients, or different condition regimens.
Regarding relapse, although there was high early 100%
chimerism in the BuCy group, there was also high percentage
of relapse in the same group. This is probably because
that group had the longest follow-up. We started sending
busulfan kinetics in our center in 2013. In the BuCy group
some patients had follow-up (up to 3432 days) compared
to FluBu4 with no PK (up to 2945 days) and the shortest
follow-up was for FluBu4 with PK (up to 1373 days) which
might explain more reported relapse in the BuCy group.
In addition, mechanisms of early relapse are different than
those of late relapse, as early relapse can be prevented by
modifying the chemotherapy regimen or preemptive therapy
with immunotherapy while late relapse might be related to
other mechanisms like escape from the powerful cytotoxic
effect of human leukocyte antigen-mismatched donor T cells
[26, 27]. So when we looked at relapse in the first 3 months,
there was a tendency for higher relapse in the FluBu4 with
no PK compared to the other 2 groups, which was not
statistically significant.
Regarding GVHD, there was no difference between the 3
groups in our study, similar to what was found by a meta-
analysis by Ben-Barouch et al. In that analysis when they
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looked at the randomized trials only, the risk grade II–IV
acute GVHD was similar between the 2 groups FluBu4 and
BuCy [28].
Our study has limitations since it is a retrospective
analysis, including potential selection bias and the presence
of other confounding factors that were not measured like
fludarabine kinetics and prior therapies. In addition because
it is retrospective, wewere unable to determine any causation,
only association if any. Other limitations include the small
number of patients, the short follow-up, and the absence
of data on lineage-specific chimerism. The strengths of this
study include looking at the kinetics of chimerism and
not at just one point of time chimerism and a cohort
of adult patients with only myeloid malignancies treated
at a single center by the same physicians with uniform
peripheral blood stemcell grafts and thewidely usedBubased
myeloablative preparative regimens with the standard-of-
care methotrexate/tacrolimus-based with or without antithy-
mocyte globulin GVHD prophylaxis.
5. Conclusion
Currently, there are no guidelines on how and when to
performpersonalized dosing of Bu as part of the conditioning
regimen prior to SCT. Chimerism is one of the methods
used to monitor disease after SCT. However, interpretation
of the results and techniques is not yet standardized. In this
small cohort, we found that patients with myeloid disorders
who received FluBu4 with Bu PK had a trend for higher
donor chimerism similar to BuCy on day 100, while FluBu4
with no PK had a tendency to lose donor chimerism by
day 100 and had more patients with less than 95% donor
chimerism by day 30. Thus, in the era of precision medicine,
the conditioning regimens and personalized dosing may
impact early donor chimerism. This is especially important
in myeloid disorders. This will need to be examined in
larger retrospective multicenter studies like CIBMTR and
prospective clinical trials.
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